An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511267-28-00

Acronym

BGB-3111-LTE1

Enrollment

343

Registered

2024-03-07

Start date

2021-02-17

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell malignancies

Brief summary

The primary endpoint of the study is safety as assessed by incidence of all TEAEs and SAEs.

Detailed description

Progression-free Survival per investigator assessment, Duration of Response per investigator assessment, Overall Survival

Interventions

DRUGZanubrutinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint of the study is safety as assessed by incidence of all TEAEs and SAEs.	—

Secondary

Measure	Time frame
Progression-free Survival per investigator assessment, Duration of Response per investigator assessment, Overall Survival	—

Countries

Czechia, France, Germany, Greece, Italy, Netherlands, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026